BioLife Solutions (NASDAQ:BLFS) Downgraded to Hold Rating by Maxim Group

Maxim Group lowered shares of BioLife Solutions (NASDAQ:BLFS) from a strong-buy rating to a hold rating in a research note released on Wednesday morning,Zacks.com reports.

A number of other analysts have also issued reports on BLFS. HC Wainwright lowered BioLife Solutions from a “buy” rating to a “neutral” rating and cut their target price for the company from $32.00 to $31.00 in a research report on Thursday. Lake Street Capital lowered BioLife Solutions from a “buy” rating to a “hold” rating and lowered their price target for the stock from $33.00 to $31.00 in a research report on Wednesday. Zacks Research cut BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 12th. Craig Hallum downgraded BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. in a report on Wednesday. Finally, TD Cowen lowered BioLife Solutions from a “buy” rating to a “hold” rating and decreased their target price for the stock from $33.00 to $31.00 in a research note on Wednesday. One research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $31.43.

BioLife Solutions Stock Performance

BioLife Solutions stock opened at $30.77 on Wednesday. The company’s 50 day simple moving average is $26.76 and its 200-day simple moving average is $23.50. BioLife Solutions has a 1 year low of $17.86 and a 1 year high of $32.23. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of -384.58 and a beta of 1.94.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. The firm had revenue of $27.50 million during the quarter, compared to analysts’ expectations of $25.66 million. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. Equities analysts expect that BioLife Solutions will post 0.02 earnings per share for the current year.

Insider Buying and Selling at BioLife Solutions

In related news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $23.70, for a total transaction of $15,405,000.00. Following the sale, the insider directly owned 4,757,165 shares of the company’s stock, valued at $112,744,810.50. This represents a 12.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 1,200,000 shares of company stock valued at $28,125,000 in the last ninety days. Insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On BioLife Solutions

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BLFS. Jacobs Levy Equity Management Inc. purchased a new stake in shares of BioLife Solutions during the first quarter worth $283,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in BioLife Solutions by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider’s stock valued at $489,000 after purchasing an additional 914 shares during the period. Jane Street Group LLC purchased a new position in BioLife Solutions in the first quarter valued at $1,091,000. Strs Ohio acquired a new position in BioLife Solutions during the 1st quarter worth $153,000. Finally, Qube Research & Technologies Ltd grew its stake in BioLife Solutions by 2,399.5% during the 2nd quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider’s stock worth $5,352,000 after purchasing an additional 238,533 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

BioLife Solutions News Summary

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: BioLife’s pending acquisition by Repligen underscores strategic value in its cell-therapy and biopreservation business, with analysts noting potential revenue and EPS benefits from the deal. Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
• Neutral Sentiment: HC Wainwright reiterated a Neutral view and a $31 price target while publishing 2027 earnings estimates of $0.03-$0.05 per share, suggesting modest longer-term profitability expectations. BioLife Solutions analyst estimates
• Neutral Sentiment: HC Wainwright’s quarterly estimates indicate expected earnings improvement into 2027, but the forecasts are not materially above the current valuation narrative. BioLife Solutions analyst estimates
• Negative Sentiment: Maxim Group downgraded BioLife Solutions from Strong Buy to Hold, a sign that enthusiasm for the shares is fading after the recent run-up. Maxim Group downgrade
• Negative Sentiment: TD Cowen also cut BioLife to Hold, adding to the cautious analyst tone around the stock. TD Cowen downgrade
• Negative Sentiment: Investigation headlines from multiple law firms over whether BioLife shareholders are receiving a fair price in the Repligen deal are creating uncertainty around the transaction. Shareholder investigation

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.